TAS-102
- Generic Name
- TAS-102
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- -
- CAS Number
- 733030-01-8
- Unique Ingredient Identifier
- -
- Background
TAS-102 (Taiho Pharma USA, Inc.) is an anti-cancer drug under development and in stage 3 clinical trials for the treatment of colorectal cancer. It is composed of the thymidine phosphorylase inhibitor (TPI) tipiracil and the cytotoxin trifluridine. Trifluridine inhibits tumor growth by being incorporated into DNA during DNA synthesis. Tipiracil prevents trif...
- Indication
用于治疗曾经接受氟嘧啶，奥沙利铂和伊立替康为基础的化疗，抗VEGF生物治疗和抗EGFR治疗（如果是RAS野生型）无效的转移性结直肠癌患者。
- Associated Conditions
- -
- Associated Therapies
- -
Trametinib and Trifluridine and Tipiracil Hydrochloride in Treating Patients With Colon or Rectal Cancer That is Advanced, Metastatic, or Cannot Be Removed by Surgery
- Conditions
- Metastatic Colon CarcinomaMetastatic Colorectal CarcinomaMetastatic Rectal CarcinomaRAS Family Gene MutationStage III Colon Cancer AJCC v7Stage III Colorectal Cancer AJCC v7Stage III Rectal Cancer AJCC v7Stage IIIA Colon Cancer AJCC v7Stage IIIA Colorectal Cancer AJCC v7Stage IIIA Rectal Cancer AJCC v7
- Interventions
- First Posted Date
- 2017-10-23
- Last Posted Date
- 2024-04-08
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 26
- Registration Number
- NCT03317119
- Locations
- 🇺🇸
City of Hope Antelope Valley, Lancaster, California, United States
🇺🇸City of Hope Corona, Corona, California, United States
🇺🇸City of Hope Medical Center, Duarte, California, United States
Study of TAS-102 Plus Radiation Therapy for the Treatment of the Liver in Patients With Hepatic Metastases From Colorectal Cancer
- First Posted Date
- 2017-07-21
- Last Posted Date
- 2022-09-08
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 56
- Registration Number
- NCT03223779
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Safety of TAS-102 in Combination With Temozolomide for Metastatic Pancreatic NETs
- Conditions
- Interventions
- First Posted Date
- 2016-10-25
- Last Posted Date
- 2022-09-23
- Lead Sponsor
- University of Wisconsin, Madison
- Target Recruit Count
- 18
- Registration Number
- NCT02943733
- Locations
- 🇺🇸
University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States
TAS-102 (Lonsurf) in Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma Post First Line Chemotherapy (UF-STO-PANC-003)
- First Posted Date
- 2016-10-03
- Last Posted Date
- 2021-02-04
- Lead Sponsor
- University of Florida
- Target Recruit Count
- 7
- Registration Number
- NCT02921737
- Locations
- 🇺🇸
UF Health Cancer Center, Gainesville, Florida, United States
🇺🇸Tallahasee Memorial HealthCare, Tallahassee, Florida, United States
🇺🇸Malcom Randall VA Medical Center, Gainesville, Florida, United States
TAS-102 in Previously Treated Unresectable or Metastatic Squamous Cell Lung Carcinoma (UF-STO-LUNG-003)
- First Posted Date
- 2016-09-30
- Last Posted Date
- 2022-06-23
- Lead Sponsor
- University of Florida
- Target Recruit Count
- 4
- Registration Number
- NCT02920476
- Locations
- 🇺🇸
UF Health Cancer Center, Gainesville, Florida, United States
A Study Evaluating TAS-102 Plus Nivolumab in Patients With MSS CRC
- Conditions
- Interventions
- First Posted Date
- 2016-08-09
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- Taiho Oncology, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT02860546
- Locations
- 🇺🇸
Florida Cancer Specialists, Sarasota, Florida, United States
🇺🇸Sarah Cannon Research Institute, Nashville, Tennessee, United States
🇺🇸Sarah Cannon Research Institute at HealthONE, Denver, Colorado, United States
Ph 2 Study of TAS-102 / Bevacizumab Maintenance Therapy Post Induction Chemotherapy in Metastatic Colorectal Cancer
- First Posted Date
- 2016-01-13
- Last Posted Date
- 2018-08-07
- Lead Sponsor
- Georgetown University
- Target Recruit Count
- 4
- Registration Number
- NCT02654639
- Locations
- 🇺🇸
Georgetown University, Washington, District of Columbia, United States
Tas-102 and Radioembolization With 90Y Resin Microspheres for Chemo-refractory Colorectal Liver Metastases
- Conditions
- Interventions
- First Posted Date
- 2015-11-11
- Last Posted Date
- 2022-08-01
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 21
- Registration Number
- NCT02602327
- Locations
- 🇺🇸
University of California San Francisco, San Francisco, California, United States
Study of TAS-102 or Placebo Plus BSC in Patients With Metastatic Gastric Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-07-16
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- Taiho Oncology, Inc.
- Target Recruit Count
- 507
- Registration Number
- NCT02500043
- Locations
- 🇺🇸
Los Angeles Cancer Network, Los Angeles, California, United States
🇺🇸Alta Bates Summit Comprehensive Cancer Center, Berkeley, California, United States
🇺🇸Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Renal Impairment
- First Posted Date
- 2014-11-25
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- Taiho Oncology, Inc.
- Target Recruit Count
- 43
- Registration Number
- NCT02301117
- Locations
- 🇺🇸
Cleveland Clinical Site, Cleveland, Ohio, United States
🇺🇸Boston Clinical Site, Boston, Massachusetts, United States
🇷🇸Sremska Kamenica Clinical Site, Sremska Kamenica, Serbia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.